A Phase 3 interventional study of Alectinib and Crizotinib in Neoplasms, sponsored by Hoffmann-La Roche. Completed at 29 sites in 9 countries. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 50 is below the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive alectinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
Drug: Alectinib
Participants will receive crizotinib at the same dose and schedule and according to the same administration guidelines as they received at the time of discontinuation from the parent trial.
Drug: Crizotinib
Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
An AE is any untoward medical occurrence in a participant administered a study drug, regardless of causal relationship. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a medically important event. AESI included drug induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice and suspected transmission of infectious agent via study drug.
Time frame: From study initiation until 4 weeks after the last dose (up to approximately 8.19 years)
Number and Causes of Death on Study
Time frame: Up to approximately 8.19 years
A total of 50 participants with anaplastic lymphoma kinase (ALK)-positive or rearranged during transfection (RET)-positive cancer took part in the rollover study at 30 investigative sites across 9 countries from 5 July 2017 to 18 September 2025.
| Milestone | Alectinib |
|---|---|
| Started | 50 |
| Completed | 35 |
| Not completed | 15 |
| Withdrew: Death | 1 |
| Withdrew: Progressive disease | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Reason not specified | 12 |
An AE is any untoward medical occurrence in a participant administered a study drug, regardless of causal relationship. A SAE is any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a medically important event. AESI included drug induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice and suspected transmission of infectious agent via study drug.
| Participants | Alectinib |
|---|---|
| AEs | 36 |
| SAEs | 6 |
| AESI | 0 |
| Participants | Alectinib |
|---|---|
| Number and Causes of Death on Study | 1 |
Collected over From study initiation until 4 weeks after the last dose (up to approximately 8.19 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alectinib | 1/50 (2%) | 6/50 (12%) | 23/50 (46%) |
| Event | Alectinib |
|---|---|
| PainGeneral disorders | 1/50 |
| PneumoniaInfections and infestations | 1/50 |
| Respiratory tract infectionInfections and infestations | 1/50 |
| SalmonellosisInfections and infestations | 1/50 |
| Cerebrovascular accidentNervous system disorders | 1/50 |
| SeizureNervous system disorders | 1/50 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/50 |
| Event | Alectinib |
|---|---|
| HeadacheNervous system disorders | 6/50 |
| AstheniaGeneral disorders | 5/50 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/50 |
| Blood creatine phosphokinase increasedInvestigations | 4/50 |
| DysphagiaGastrointestinal disorders | 3/50 |
| NauseaGastrointestinal disorders | 3/50 |
| VomitingGastrointestinal disorders | 3/50 |
| Oedema peripheralGeneral disorders | 3/50 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/50 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 3/50 |
Safety Population included all enrolled participants who received at least one dose of study drug.
| Age, Continuous(Years) | Alectinib |
|---|---|
| Mean | 56.6 ± 11.8 |
| Sex: Female, Male(Participants) | Alectinib |
|---|---|
| Female | 30 |
| Male | 20 |
| Ethnicity (NIH/OMB)(Participants) | Alectinib |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 44 |
| Unknown or Not Reported | 5 |
| Race (NIH/OMB)(Participants) | Alectinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 37 |
| More than one race | 0 |
| Unknown or Not Reported | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Jul 2017 to primary completion in Sep 2025, 98 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 98 months is above that.
Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alectinib · Crizotinib